Skip to content
Article Rich – Lifestyle
Author:
Certara
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
May 21, 2026
Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
April 30, 2026
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
April 29, 2026
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting
April 23, 2026
Certara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to Veristat
April 22, 2026
Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy
April 21, 2026
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
April 20, 2026
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
March 18, 2026
Genprex to Participate at BIO Europe Spring 2026
March 10, 2026
Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib
March 5, 2026
←
Previous Page
1
2
3
Next Page
→